Navigation Links
DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
Date:2/12/2009

ransplantation centers in the US and France. Although orBec(R) did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec(R) did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec(R) at 200 days post-transplant with only 5 patient (8%) deaths in the orBec(R) group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139). At one year post randomization in the pivotal Phase 3 trial, 18 patients (29%) in the orBec(R) group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, hazard ratio 0.54, 95% CI: 0.30, 0.99, p=0.04, stratified log-rank test).

In the Phase 2 study, the primary endpoint was the clinically relevant determination of whether GI GVHD patients at Day 30 (the end of treatment) had a durable GVHD treatment response as measured by whether or not they were able to consume at least 70% of their estimated caloric requirement. The GVHD treatment response at Day 30 was 22 of 31 (71%) vs. 12 of 29 (41%) in the orBec(R) and placebo groups, respectively (p-value 0.02). Additionally, the GVHD treatment response at Day 40 (10 days post cessation of therapy) was 16 of 31 (52%) vs. 5 of 29 (17%) in the orBec(R) and placebo groups, respectively (p-value 0.007).

orBec(R) represents a first-of-its-kind oral, locally acting therapy tailored to treat the gastrointestinal manifestation of GVHD, the organ system where GVHD is most frequently encountered and highly problematic. orBec(R) is intended to reduce the need for systemic immunosuppressive drugs to treat GI GVHD. Beclomethasone
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
2. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
3. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
4. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
6. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
7. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
8. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
9. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
10. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Air Conditioning & Heating Inc. ... authorized Daikin comfort pro dealer. This means that the ... and cooling system equipment. Only a select few businesses ... before being approved. , Daikin co-developed an R-410A refrigerant ... System Air Conditioning Market. They are also the inventor ...
(Date:7/22/2014)... Alexandria, Va. (PRWEB) July 22, 2014 ... Sept. 10, at the Ronald Reagan Building and ... “Transitioning Forward: Warriors, Military Families and Civilian Communities,” ... p.m., (registration opens at 7:30 a.m.) and cohosted ... and the National Defense Industrial Association (NDIA). USAA ...
(Date:7/22/2014)... 22, 2014 A Florida woman has ... that alleges the death of her husband was the ... thinner, Bernstein Liebhard LLP reports. According to her complaint, ... for the Southern District of Florida on June 23rd, ... suffered a subdural hemorrhage the following June. Despite emergency ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor Tomas ... Los Angeles with the 2014 E. Donnall Thomas Lecture ... discovery of the iron-regulatory hormone hepcidin and investigation of ... the Nobel Prize Laureate and past Society president E. ... that have represented a paradigm shift or significant discovery ...
(Date:7/22/2014)... Plate Club you eat pretty much everything you put ... Cornell University study shows that the average adult eats 92% ... plate. "If you put it on your plate, ... of the forthcoming book, Slim by Design, Professor of Marketing ... Wansink and co-author Katherine Abowd Johnson analyzed 1179 diners and ...
Breaking Medicine News(10 mins):Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3
... Revenues increase 166% versus Q1 2007 ... Six new Centers opened to date in 2008, VANCOUVER, May ... revenues of $1.35 million for,the three months ended March 31, 2008 ... an increase of 166%. The Company,s net,loss decreased to $0.96 million ...
... Israel, May 29 Elbit Imaging Ltd.,(Nasdaq: EMITF ... for the,first quarter of 2008., Loss for the ... US$ 1.0 million) of which loss of NIS 27.3 ... holders of,the Company, while profit of NIS 23.8 million ...
... from the Oregon Health & Science University Cancer Institute ... hope to many patients. , Researchers have discovered that ... can occur in a gene called the KIT gene. ... and mucosal melanomas, which are less common, but highly ...
... bacteria break their metabolic processes into chunks. That may ... have now figured out the factors that tend to ... Santa Fe Institute and Stanford University, together with Anat ... University, constructed the metabolic networks of many species of ...
... Society for Therapeutic Radiology has selected the recipients of ... bestows. Christopher Rose, M.D., FASTRO, and Joel Tepper, M.D., ... 50th Annual Meeting in Boston during the Gold Medal ... "It seems particularly fitting that we recognize these two ...
... risk of dying within month, study finds , , THURSDAY, May ... more likely to die within 30 days than stroke patients ... Seizures may be a sign of significant brain injury and ... This study found that the overall incidence of seizures within ...
Cached Medicine News:Health News:CRH Medical reports Q1 2008 results 2Health News:CRH Medical reports Q1 2008 results 3Health News:CRH Medical reports Q1 2008 results 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 2Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 3Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 5Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 6Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 7Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 8Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 9Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 10Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 11Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 12Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 13Health News:OHSU Cancer Instutute researchers find abnormalities in gene for melanoma 2Health News:ASTRO announces 2008 gold medalists 2
(Date:7/22/2014)... 22, 2014 Research and Markets ... Market by Equipment, by Reagent, by Application - Global ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals ... is one of the most important and widely used ... application segment of the cell culture market in 2013. ...
(Date:7/22/2014)... , July 22, 2014  Decision Resources ... multiple sclerosis (MS) patients currently treated with ... have ever experienced flushing and/or gastrointestinal events ... patients are currently experiencing these side effects, ... effective medical management of such events. In ...
(Date:7/22/2014)... , July 22, 2014 The number of ... 45 people each day. Twenty-three percent of the workforce ... on Drug Use and Health, making opioid use a ... taking opioid painkillers at the correct dosage with a ... Today, the National Safety Council released ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 35 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3
... LOS ANGELES, March 22, 2011 UBM Canon,s Medical ... EMDT ( European Medical Device Technology ), ... and Qmed, the world,s only 100% qualified ... a combined virtual conference and tradeshow focusing on current ...
... Inc. has expanded its line of RFID-enabled enclosures with ... for hospital and laboratory inventory management . Leveraging ... use of space, reduces energy consumption, lowers maintenance costs, ... products, tissue samples, and orthopedic supplies.   ...
Cached Medicine Technology:EMDT, MD+DI, and Qmed Announce Virtual Event Dedicated to Developments in Materials for Medical Applications 2EMDT, MD+DI, and Qmed Announce Virtual Event Dedicated to Developments in Materials for Medical Applications 3EMDT, MD+DI, and Qmed Announce Virtual Event Dedicated to Developments in Materials for Medical Applications 4Terso Solutions Launches New RFID-Enabled Refrigerator for Hospital and Laboratory Inventory Management 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: